Tuberculosis (TB) and Multidrug resistant tuberculosis (MDR) are important diseases that affect children globally. TB is still a cause of morbidity and mortality in many low to middle income country settings but is also increasingly seen in Europe, more so in Eastern European countries. Challenges with diagnosis of TB and duration of treatment and registration of new drugs are new opportunities for combating TB in 2022.
Educational aims
There have been recent advances in TB and MDR treatment options in the last decade for paediatric TB. The addition of new anti-TB drugs like Bedaquiline, Delamanid and Pretomanid have revolutionised TB treatments and duration of therapy. Repurposing of old drugs to add to TB drug armamentarium and also newer child friendly drugs have changed the face of TB therapy. This webinar will address the role of new and old repurposed drugs in TB treatment and gaps in current therapies.
Topics
TB treatment, Treatment duration, Side effects, Future drugs and drug trials.
Format
2 lectures, each 20 minutes long, followed by a 20-minute Q&A session.
Learning outcomes
An understanding of the various treatment options available to treat both TB and MDR TB as well as the new drugs that are currently in trial phase for TB/MDR TB.
More information
This webinar is organised directly by the Pan African Thoracic Society (PATS). For any questions including registration, technical and log in details, please contact PATS directly in this link.
Diseases / methods
- Paediatric respiratory diseases
Target audience
- Paediatric pulmonologists
- Paediatricians
- General practitioners
- Paediatric trainees
- Paediatric pulmonology fellows
- Respiratory therapists